ProfileGDS5678 / 1432990_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 19% 19% 18% 19% 18% 28% 17% 22% 18% 18% 18% 19% 18% 18% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.4744219
GSM967853U87-EV human glioblastoma xenograft - Control 22.4460619
GSM967854U87-EV human glioblastoma xenograft - Control 32.4433918
GSM967855U87-EV human glioblastoma xenograft - Control 42.4034919
GSM967856U87-EV human glioblastoma xenograft - Control 52.3888118
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7155428
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.4487617
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.5107922
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4125518
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.430118
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.4295518
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4340519
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.4307318
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4363118